These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Targeted therapy for solid tumors: current status. Zureikat AH; McKee MD Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353 [TBL] [Abstract][Full Text] [Related]
47. Clinical year in review I: lung cancer, interventional pulmonology, noninvasive mask ventilation, and pulmonary vascular disease. Trow TK Proc Am Thorac Soc; 2005; 2(2):102-4. PubMed ID: 16113476 [No Abstract] [Full Text] [Related]
48. Intracellular signals of lung cancer cells as possible therapeutic targets. Tanaka K; Kumano K; Ueno H Cancer Sci; 2015 May; 106(5):489-96. PubMed ID: 25707772 [TBL] [Abstract][Full Text] [Related]
49. New skin cancer target could delay drug resistance. Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687783 [No Abstract] [Full Text] [Related]
50. Personalized lung cancer treatment based on molecular determinants. Simon GR J S C Med Assoc; 2011 Oct; 107(5):183-4. PubMed ID: 22057801 [No Abstract] [Full Text] [Related]
51. Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine. Dumur CI; Idowu MO; Powers CN Cancer Cytopathol; 2013 Feb; 121(2):61-71. PubMed ID: 22887782 [TBL] [Abstract][Full Text] [Related]
52. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Passiglia F; Caparica R; Giovannetti E; Giallombardo M; Listi A; Diana P; Cirrincione G; Caglevic C; Raez LE; Russo A; Rolfo C Expert Opin Investig Drugs; 2016; 25(4):385-92. PubMed ID: 26881293 [TBL] [Abstract][Full Text] [Related]
53. Synthetic lethal vulnerabilities of cancer. Fece de la Cruz F; Gapp BV; Nijman SM Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932 [TBL] [Abstract][Full Text] [Related]
55. [Mechanisms of resistance to target therapy]. Matsusaka S Nihon Rinsho; 2012 Dec; 70(12):2195-8. PubMed ID: 23259396 [TBL] [Abstract][Full Text] [Related]
56. [Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy]. Zhang G; Wang H; Zhang M; Li P; Ma Z Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):587-91. PubMed ID: 26383984 [TBL] [Abstract][Full Text] [Related]
57. Targeting signaling pathways in lung cancer therapy. Cho WC Expert Opin Ther Targets; 2013 Feb; 17(2):107-11. PubMed ID: 23231077 [TBL] [Abstract][Full Text] [Related]
58. Scientists develop new tool for targeted cancer drug development. Printz C Cancer; 2012 Jun; 118(12):3001. PubMed ID: 22674499 [No Abstract] [Full Text] [Related]
59. Advances in targeting signal transduction pathways. McCubrey JA; Steelman LS; Chappell WH; Sun L; Davis NM; Abrams SL; Franklin RA; Cocco L; Evangelisti C; Chiarini F; Martelli AM; Libra M; Candido S; Ligresti G; Malaponte G; Mazzarino MC; Fagone P; Donia M; Nicoletti F; Polesel J; Talamini R; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Michele M; Tafuri A; Dulińska-Litewka J; Laidler P; D'Assoro AB; Drobot L; Umezawa D; Montalto G; Cervello M; Demidenko ZN Oncotarget; 2012 Dec; 3(12):1505-21. PubMed ID: 23455493 [TBL] [Abstract][Full Text] [Related]
60. Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. Morgensztern D; Govindan R Clin Lung Cancer; 2014 Jan; 15(1):16-20. PubMed ID: 24377742 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]